Payment overview · 2025
General Payments
$1,092.66
47 reported records · 14 companies
Healthcare provider profile · identity verified
Anna Chernyak, MD
Allopathic & Osteopathic Physicians|Internal Medicine · UNION, NJ · NPI 1558437665
Verified facts
What the public records show
CMS Open Payments records show Anna Chernyak, MD received $1,092.66 in general payments during 2025 across 47 reported records.
AstraZeneca Pharmaceuticals LP accounted for 35.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Jardiance, Linzess, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $392.33 | 35.9% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $211.85 | 19.4% | 17 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $88.71 | 8.1% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $81.24 | 7.4% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $74.60 | 6.8% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $55.24 | 5.1% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $51.26 | 4.7% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $34.37 | 3.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $24.22 | 2.2% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $19.72 | 1.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.83 | 1.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $15.04 | 1.4% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $14.17 | 1.3% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.08 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,092.66 | 47 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $276.33 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $205.48 | 16 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $151.33 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $116.00 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $92.94 | 6 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $88.71 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $62.90 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $55.24 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $55.24 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $51.26 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $34.37 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $24.22 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $24.22 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $19.72 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $15.04 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $14.17 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.08 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $6.37 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $6.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 97 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 102 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 83 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
83 | 21 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
97 | 20 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
102 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
102 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 274 | 66 |
| Losartan Potassium | Losartan Potassium | 265 | 59 |
| Meloxicam | Meloxicam | 214 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 185 | 51 |
| Furosemide | Furosemide | 180 | 44 |
| Glimepiride | Glimepiride | 166 | 28 |
| Simvastatin | Simvastatin | 153 | 44 |
| Gabapentin | Gabapentin | 143 | 31 |
| Atorvastatin Calcium | Atorvastatin Calcium | 137 | 37 |
| Levothyroxine Sodium | Levothyroxine Sodium | 127 | 28 |
| Sertraline Hcl | Sertraline Hcl | 123 | 33 |
| Metformin Hcl | Metformin Hcl | 121 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 119 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 117 | 37 |
| Alendronate Sodium | Alendronate Sodium | 111 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 109 | 23 |
| Ezetimibe | Ezetimibe | 105 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 104 | 29 |
| Jardiance | Empagliflozin | 102 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 99 | 23 |
| Farxiga | Dapagliflozin Propanediol | 97 | 20 |
| Spironolactone | Spironolactone | 97 | 19 |
| Allopurinol | Allopurinol | 95 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 94 | 23 |
| Alprazolam | Alprazolam | 88 | 14 |
| Famotidine | Famotidine | 84 | 18 |
| Linzess | Linaclotide | 83 | 21 |
| Prednisone | Prednisone | 83 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 81 | 19 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 79 | 27 |
| Carvedilol | Carvedilol | 73 | 17 |
| Bupropion Xl | Bupropion Hcl | 65 | 17 |
| Clonazepam | Clonazepam | 64 | 19 |
| Digoxin | Digoxin | 64 | 14 |
| Azithromycin | Azithromycin | 63 | 53 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 62 | suppressed |
| Mirtazapine | Mirtazapine | 61 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 57 | 18 |
| Omeprazole | Omeprazole | 57 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 53 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 52 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 51 | suppressed |
| Lisinopril | Lisinopril | 50 | 13 |
| Carvedilol Er | Carvedilol Phosphate | 49 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 48 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 48 | 17 |
| Leflunomide | Leflunomide | 47 | 14 |
| Trazodone Hcl | Trazodone Hcl | 45 | 13 |
| Xarelto | Rivaroxaban | 44 | 13 |
| Propranolol Hcl Er | Propranolol Hcl | 42 | 13 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 41 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 40 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 39 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 37 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 35 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 35 | 16 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 35 | suppressed |
| Nabumetone | Nabumetone | 34 | 15 |
| Eliquis | Apixaban | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Levetiracetam | Levetiracetam | 33 | suppressed |
| Nitroglycerin | Nitroglycerin | 33 | 14 |
| Buspirone Hcl | Buspirone Hcl | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 32 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 21 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 27 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 27 | suppressed |
| Restasis | Cyclosporine | 27 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | suppressed |
| Clarithromycin | Clarithromycin | 26 | 23 |
| Diazepam | Diazepam | 26 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Ozempic | Semaglutide | 25 | suppressed |
| Repatha Sureclick | Evolocumab | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 23 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 22 | 12 |
| Prolia | Denosumab | 22 | 14 |
| Edarbi | Azilsartan Medoxomil | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Methotrexate | Methotrexate Sodium | 20 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Cilostazol | Cilostazol | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Folic Acid | Folic Acid | 18 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 16 | suppressed |
| Pentoxifylline | Pentoxifylline | 16 | suppressed |
| Procto-Med Hc | Hydrocortisone | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 15 | 14 |
| Creon | Lipase/Protease/Amylase | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 12 |
| Zenpep | Lipase/Protease/Amylase | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Otezla | Apremilast | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Easy Comfort Pen Needles | Pen Needle, Diabetic | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Terconazole | Terconazole | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,092.66 · 47 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AUSTEDO XR, BREZTRI, CREON, ELIQUIS, FANAPT, FARXIGA, INGREZZA, JARDIANCE, LEQVIO, LINZESS, MOUNJARO, NEXLETOL, NURTEC ODT, Ozempic, REXULTI, Rybelsus, TRINTELLIX, The Cologuard Plus Collection Kit, VRAYLAR | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error